Wednesday 28 February 2024
Salisbury Foundation Trust

FOI_7473

Internal Reference Number: FOI_7473

Date Request Received: 09/10/2023 00:00:00

Date Request Replied To: 01/11/2023 00:00:00

This response was sent via: By Email

Request Summary: Lung cancer

Request Category: Researcher

 
Question Number 1:
How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

• ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)

• Amivantamab

• Atezolizumab Monotherapy

• Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel

• Dabrafenib + Trametinib

• Docetaxel monotherapy or in combination with Carboplatin/Cisplatin

• Durvalumab

• Gemcitabine

• Nitedanib + Docetaxel

• Nivolumab

• Osimertinib

• Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)

• Paclitaxel

• Pembrolizumab Monotherapy

• Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)

• Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)

• Pemetrexed + Platinum (Carboplatin/Cisplatin)

• RET Inhibitors (Pralsetinib, Selpercatinib)

• Sotorasib

• Tepotinib

• Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin

• Other active systemic anti-cancer therapy

• Palliative care only
 
Answer To Question 1:
Q. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

• ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) <5

• Amivantamab 0

• Atezolizumab Monotherapy <5

• Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 0

• Dabrafenib + Trametinib <5

• Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0

• Durvalumab <5

• Gemcitabine 0

• Nitedanib + Docetaxel 0

• Nivolumab <5

• Osimertinib <5

• Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 0

• Paclitaxel 0

• Pembrolizumab Monotherapy <5

• Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 0

• Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 5

• Pemetrexed + Platinum (Carboplatin/Cisplatin) <5

• RET Inhibitors (Pralsetinib, Selpercatinib) 0

• Sotorasib <5

• Tepotinib <5

• Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin <5

• Other active systemic anti-cancer therapy <5 (Cisplain/gemcitabine)

• Palliative care only - Unable to answer, information not held
 
Question Number 2:
Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.
 
Answer To Question 2:
no
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 Salisbury NHS Foundation Trust
Trust Values